| Nov 13 |
Evercore Downgrades Savara on Manufacturing Concerns for Lung Disease Drug Candidate
|
| Nov 13 |
Savara downgraded at Evercore on manufacturing concerns for lung disease candidate
|
| Nov 13 |
Savara Announces Participation in Upcoming Healthcare Conferences
|
| Nov 12 |
Savara GAAP EPS of -$0.11 in-line
|
| Nov 12 |
Savara Reports Third Quarter 2024 Financial Results and Provides Business Update
|
| Nov 4 |
Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference
|
| Oct 22 |
Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of "The Balancing Act®" Airing on Lifetime® TV
|
| Oct 18 |
Savara Announces New Employment Inducement Grant
|
| Oct 1 |
Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting
|
| Sep 27 |
Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
|
